 |
 |

Glucose-Insulin-Potassium Therapy in Patients With STEMI
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
To the Editor: We have concerns about possible conclusions of the study of glucose-insulin-potassium (GIK) therapy in patients with ST-segment elevation myocardial infarction (STEMI) by Dr Díaz and colleagues,1 which combined patients from the early-terminated OASIS-6 (Organization for the Assessment of Strategies for Ischemic Syndromes 6) trial with their previously published CREATE-ECLA Trial (Clinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment and Evaluation–Estudios Clinicos Latino America).2 In the earlier article, the investigators commented on a possible relationship between hyperglycemia and mortality. In a post hoc analysis in the study by Díaz et al,1 there was again an association of higher glucose with greater event rates, consistent with the association of diabetes mellitus with elevated glucose and with worse acute myocardial infarction (MI) outcomes.3 We do not believe that an inference of a causal link between mortality and GIK is justified by these data.
The post hoc . . . [Full Text of this Article]
Harry P. Selker, MD, MSPH
hselker@tufts-nemc.org Tufts-New England Medical Center Boston, Massachusetts
Joanne Ingwall, PhD
Harvard Medical School Boston
Charles E. Rackley, MD
Georgetown Medical Center Washington, DC
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points
Goyal et al.
Diabetes and Vascular Disease Research 2008;5:276-284.
ABSTRACT
|